文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺癌两分次立体定向消融放疗后毒性与生活质量的剂量学相关因素

Dosimetric correlates of toxicities and quality of life following two-fraction stereotactic ablative radiotherapy (SABR) for prostate cancer.
PubMed 文献 · Radiother Oncol · 2023-08-22

基于两项前瞻性试验(2STAR与2SMART)共60例接受两分次前列腺立体定向消融放疗的患者个体数据,中位随访56个月,分析剂量学参数与毒性和生活质量的关系。膀胱0.5cc是晚期≥2级泌尿生殖毒性的显著预测因子,最佳截断值为25.5 Gy;阴茎球D5cc与晚期≥2级性毒性相关,未确定最佳截断值。

要点

  • 膀胱0.5cc是晚期≥2级泌尿生殖毒性的显著预测因子,最佳截断值25.5 Gy。
  • 阴茎球D5cc与晚期≥2级性毒性相关,未确定最佳截断值。
  • 未发现其他剂量学参数与其他结局相关。

核心结论

  • 利用前瞻性试验的中期随访真实患者数据,识别出可能减轻两分次前列腺SABR晚期治疗相关毒性风险的额外剂量约束。

研究设计与样本

  • 纳入2STAR(NCT02031328)和2SMART(NCT03588819)两项前瞻性试验中接受两分次前列腺SABR的60例患者。
  • 处方剂量为前列腺26 Gy,±优势前列腺内病灶推量32 Gy。
  • 毒性及生活质量数据前瞻性收集,采用CTCAEv4和EPIC-26问卷。
  • 评估结局为急性和晚期≥2级毒性,以及生活质量领域的晚期最小临床重要变化(MCIC)。
  • 评估膀胱、尿道、直肠和阴茎球的剂量学参数。

主要发现

  • 中位随访56个月(范围39-78个月)。
  • 急性(<3个月)≥2级泌尿生殖、胃肠道和性毒性累积发生率分别为62%、3%和17%。
  • 晚期(>6个月)≥2级泌尿生殖、胃肠道和性毒性累积发生率分别为57%、15%和52%。
  • 分别有36%、28%和29%的患者在泌尿、肠道和性生活质量结局出现晚期MCIC。
  • 膀胱0.5cc是晚期≥2级泌尿生殖毒性的显著预测因子,最佳截断值25.5 Gy;阴茎球D5cc与晚期≥2级性毒性相关,未确定最佳截断值。

关键数值与推荐

  • 膀胱0.5cc最佳截断值25.5 Gy,为晚期≥2级泌尿生殖毒性的显著预测因子。
  • 阴茎球D5cc与晚期≥2级性毒性相关,未确定最佳截断值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There is no evidence-based data to guide dose constraints in two-fraction prostate stereotactic ablative radiotherapy (SABR). Using individual patient-data from two prospective trials, we aimed to correlate dosimetric parameters with toxicities and quality of life (QoL) outcomes. MATERIALS AND METHODS: We included 60 patients who had two-fraction prostate SABR in the 2STAR (NCT02031328) and 2SMART (NCT03588819) trials. The prescribed dose was 26 Gy to the prostate+/-32 Gy boost to the dominant intraprostatic lesions. Toxicities and QoL data were prospectively collected using CTCAEv4 and EPIC-26 questionnaire. The outcomes evaluated were acute and late grade ≥ 2 toxicities, and late minimal clinical important changes (MCIC) in QoL domains. Dosimetric parameters for bladder, urethra, rectum, and penile bulb were evaluated. RESULTS: The median follow-up was 56 months (range: 39-78 months). The cumulative incidence of grade ≥ 2 genitourinary (GU), gastrointestinal (GI), and sexual toxicities were 62%, 3%, and 17% respectively in the acute setting (<3 months), and 57%, 15%, and 52% respectively in late setting (>6 months). There were 36%, 28%, and 29% patients who had late MCIC in urinary, bowel and sexual QoL outcomes respectively. Bladder 0.5 cc was significant predictor for late grade ≥ 2 GU toxicities, with optimal cut-off of 25.5 Gy. Penile bulb D5cc was associated of late grade ≥ 2 sexual toxicities (no optimal cut-off was identified). No dosimetric parameters were identified to be associated with other outcomes. CONCLUSION: Using real-life patient data from prospective trials with medium-term follow-up, we identified additional dose constraints that may mitigate the risk of late treatment-related toxicities for two-fraction prostate SABR.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Ong WL, Davidson M, Cheung P, et al. Dosimetric correlates of toxicities and quality of life following two-fraction stereotactic ablative radiotherapy (SABR) for prostate cancer. Radiother Oncol. 2023. PMID: 37619656. doi:10.1016/j.radonc.2023.109864

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。